Drug & Device ConferenceSAR-bisPSMA:A sensitive story12 October 2026For investor purposes onlyAll Clarity products mentioned in this presentation are investigational products and not approved by the US Food and Drug Administration (FDA).Dr Alan TaylorExecutive ChairpersonDisclaimerIntroductionThis...
SAR-bisPSMA Presentation - Drug & Device Conference
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
In the deck
Story so far
Earlier from Clarity Pharmaceuticals
- SECuRE update
- Becoming a substantial holder
- Corporate governance statement
- Appendix 4G
- Annual Report to shareholders
Later from Clarity Pharmaceuticals
- Ceasing to be a substantial holder
- Notice of Annual General Meeting/Proxy Form
- Ph III CLARIFY trial target number of participants achieved
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals